Mellow Hope (HTDS) Registration Certificate of Cognistar Approved in India
Marketwire “Press Releases”
SHENZHEN, CHINA — (MARKET WIRE) — 11/26/10 — Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (www.htdsmedical.com) subsidiary Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope) announces that, after four years of continuous effort, the registration of Cerebroprotein Hydrolysate for Injection (Cognistar) has been approved by India’s drug regulator, Drugs Controller General of India (DCGI).
As soon as the approval is finalized, Mellow Hope (www.mellowhope.com/en/main.asp) will launch this product in the local market. Until this point there has been no local supplier in India for Cognistar, so the company anticipates healthy sales as it fills this market vacancy and claims a large market share. The company received permit to import this product to India , and copy of this certificate will be made available @ www.htdsmedical.com. The company will also post this certificate on OTCMarkets.Com as a filing shortly.
Cognistar is a unique nutriment for the brain. It regulates and improves nerve cell metabolism, promotes synapse generation, induces nerve cell differentiation, and protects nerve cells against damages by ischemia and neurotoxins.
The company is pleased at this approval after years of diligent research, and will keep the investor public updated as the first batches of Cognistar reach the Indian market.
In other company news and updates, regarding the news of November 22, 2010 and merger progress with a Canadian based Hb Products Inc. (Hb) the company is working diligently and vigorously to have the merger completed way ahead of the Christmas holidays. Currently a new updated web site is being developed to include Hb with a preview available at this link http://www.htdsmedical.com/new/.
The management will release further updates shortly as they become available.